Total Payments
$461,650
2024 Payments
$27,405
Companies
9
Transactions
116
Medicare Patients
312
Medicare Billing
$21,691
Payment Breakdown by Category
Consulting$284,355 (61.6%)
Research$177,295 (38.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $284,355 | 62 | 61.6% |
| Unspecified | $177,295 | 54 | 38.4% |
Payments by Type
General
$284,355
62 transactions
Research
$177,295
54 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $218,890 | 40 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $76,395 | 28 | $0 (2021) |
| Dr.Reddy's Laboratories,Inc. | $48,350 | 8 | $0 (2023) |
| AstraZeneca UK Limited | $33,830 | 8 | $0 (2024) |
| Acerta Pharma LLC | $28,860 | 8 | $0 (2019) |
| AbbVie Inc. | $28,215 | 15 | $0 (2020) |
| Hoffmann-La Roche Limited | $22,525 | 1 | $0 (2017) |
| BeiGene, Ltd. | $4,375 | 7 | $0 (2024) |
| Novartis Pharma AG | $210.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,405 | 13 | AstraZeneca UK Limited ($24,420) |
| 2023 | $15,385 | 5 | AstraZeneca UK Limited ($9,410) |
| 2022 | $26,500 | 4 | Dr.Reddy's Laboratories,Inc. ($26,500) |
| 2021 | $43,825 | 17 | Dr.Reddy's Laboratories,Inc. ($15,875) |
| 2020 | $89,660 | 21 | Pharmacyclics LLC, An AbbVie Company ($52,115) |
| 2019 | $92,160 | 32 | Merck Sharp & Dohme Corporation ($40,055) |
| 2018 | $91,100 | 14 | Merck Sharp & Dohme Corporation ($74,730) |
| 2017 | $75,615 | 10 | Merck Sharp & Dohme Corporation ($52,965) |
All Payment Transactions
116 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $210.00 | Research |
| Study: CCTL019E2301 • Category: ONCOLOGY | ||||||
| 12/17/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 10/22/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $770.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,210.00 | General |
| Category: Oncology | ||||||
| 04/09/2024 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 03/19/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $7,480.00 | General |
| Category: Oncology | ||||||
| 03/19/2024 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 02/20/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $12,430.00 | General |
| Category: Oncology | ||||||
| 01/09/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,705.00 | General |
| Category: Oncology | ||||||
| 12/19/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $7,810.00 | General |
| Category: Oncology | ||||||
| 11/07/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 05/30/2023 | BeiGene, Ltd. | — | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | ||||||
| 05/16/2023 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 04/18/2023 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $3,875.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 12/20/2022 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $1,125.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 11/22/2022 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $7,500.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 09/01/2022 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 08/01/2022 | Dr.Reddy's Laboratories,Inc. | — | — | Cash or cash equivalent | $17,125.00 | Research |
| Study: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | ||||||
| 12/21/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma • Category: ONCOLOGY | ||||||
| 12/21/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | — | Cash or cash equivalent | $230.00 | Research |
| Study: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) • Category: ONCOLOGY | ||||||
| 12/01/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $61,725 | 12 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | Dr.Reddy's Laboratories,Inc. | $48,350 | 8 |
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $22,525 | 1 |
| M12-914 | AbbVie, Inc. | $22,500 | 10 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | Pharmacyclics LLC, An AbbVie Company | $6,555 | 7 |
| M12-175 | AbbVie, Inc. | $5,040 | 1 |
| Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Pharmacyclics LLC, An AbbVie Company | $3,725 | 5 |
| PCYC-1143-CA | Pharmacyclics LLC, An AbbVie Company | $2,290 | 2 |
| Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma | Pharmacyclics LLC, An AbbVie Company | $2,100 | 2 |
| Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | BeiGene, Ltd. | $1,600 | 1 |
| M12-914 | AbbVie Inc. | $375.00 | 3 |
| M12-895 | AbbVie, Inc. | $300.00 | 1 |
| CCTL019E2301 | Novartis Pharma AG | $210.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 38 | 39 | $10,072 | $655.26 |
| 2020 | 5 | 274 | 365 | $97,890 | $21,036 |
Total Patients
312
Total Services
404
Medicare Billing
$21,691
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 22 | $4,598 | $425.55 | 9.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 16 | 17 | $5,474 | $229.71 | 4.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 128 | 194 | $62,371 | $11,265 | 18.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 47 | 59 | $11,900 | $3,986 | 33.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 57 | 62 | $7,715 | $2,623 | 34.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 18 | $9,316 | $1,790 | 19.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 27 | 32 | $6,588 | $1,372 | 20.8% |
About Dr. Wb Younger, MD
Dr. Wb Younger, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285615112.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wb Younger, MD has received a total of $461,650 in payments from pharmaceutical and medical device companies, with $27,405 received in 2024. These payments were reported across 116 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($284,355).
As a Medicare-enrolled provider, Younger has provided services to 312 Medicare beneficiaries, totaling 404 services with total Medicare billing of $21,691. Data is available for 2 years (2020–2021), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 11/08/2005
- Last Updated 07/20/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285615112
Products in Payments
- KEYTRUDA (Biological) $218,890
- CALQUENCE (Drug) $62,690
- Imbruvica (Drug) $52,115
- VENCLEXTA (Biological) $22,525
- IMBRUVICA (Drug) $12,380
- Ibrutinib (Drug) $11,900
- Venclexta (Drug) $5,040
- BRUKINSA (Drug) $2,525
- KYMRIAH (Biological) $210.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795